


PRODUCT INFORMATION



KM 233

Item No. 10640

CAS Registry No.: 628263-22-9
Formal Name: 6aR,7,10,10aR-tetrahydro-6,6,9-trimethyl-3-(1-methyl-1-phenylethyl)-6H-dibenzo[b,d]pyran-1-ol
MF: C₂₅H₃₀O₂
FW: 362.5
Purity: ≥98%
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

KM 233 is supplied as a crystalline solid. A stock solution may be made by dissolving the KM 233 in the solvent of choice. KM 233 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of KM 233 in ethanol is approximately 3 mg/ml and approximately 20 mg/ml in DMSO and DMF.

KM 233 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, KM 233 should first be dissolved in DMF and then diluted with the aqueous buffer of choice. KM 233 has a solubility of approximately 0.3 mg/ml in a 1:2 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Because selective activation of peripheral cannabinoid (CB₂) receptors in rat C-6 glioma cells has been shown to induce apoptosis through enhanced ceramide synthesis *de novo*, CB₂ agonists present potential as anti glioma agents.¹ KM 233 is a Δ⁸-tetrahydrocannabinol analog with a dimethyl substitution that exhibits high binding affinity for both the CB₁ and CB₂ receptors with 13-fold selectivity for the CB₂ receptor (K_is = 12.3 and 0.91 nM, respectively).² Demonstrating good lipophilicity and ability to penetrate the blood brain barrier, KM 233 inhibits human U87 glioma cell proliferation *in vitro* with an IC₅₀ value of 1.4 μM and significantly reduces U87 glioma tumor size *in vivo* at a dose of 2 mg/kg in a SCID mouse xenograft side-pocket model.³

References

1. Sánchez, C., de Ceballos, M.L., Gomez de Pulgar, T., *et al.* Inhibition of glioma growth *in vivo* by selective activation of the CB₂ cannabinoid receptor. *Cancer Res.* **61(15)**, 5784-5789 (2001).
2. Krishnamurthy, M., Ferreira, A.M., and Moore, B.M.II. Synthesis and testing of novel phenyl substituted side-chain analogues of classical cannabinoids. *Bioorg. Med. Chem. Lett.* **13**, 3487-3490 (2003).
3. Duntsch, C., Divi, M.K., Jones, T., *et al.* Safety and efficacy of a novel cannabinoid chemotherapeutic, KM-233, for the treatment of high-grade glioma. *J. Neurooncol.* **77**, 143-152 (2006).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 07/13/2017

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM